Vigil Neuroscience, a Phase 1-ready biotech developing antibody therapies for neurodegenerative diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The company is utilizing a precision medicine approach to develop a pipeline of therapies, initially addressing genetically defined patient subpopulations, that it believes will activate and restore immune cell function within the brain. Its lead candidate, VGL101, is a fully human monoclonal antibody (mAb) that is initially being developed for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). In November 2021, the FDA cleared Vigil's IND for VGL101 in ALSP, and the company plans to begin its first-in-human Phase 1 trial this December. It expects to complete the trial in the 2H22.
The Cambridge, MA-based company was founded in 2020 and plans to list on the Nasdaq under the symbol VIGL. Vigil Neuroscience filed confidentially on October 8, 2021. Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
